Compare NNDM & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNDM | CBIO |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.7M | 488.1M |
| IPO Year | 2015 | 2013 |
| Metric | NNDM | CBIO |
|---|---|---|
| Price | $1.33 | $13.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | ★ 1.2M | 227.8K |
| Earning Date | 11-05-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $102,437,000.00 | $18,500.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.00 | $177.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 77.30 | N/A |
| 52 Week Low | $1.19 | $8.72 |
| 52 Week High | $2.32 | $27.41 |
| Indicator | NNDM | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.16 | 49.69 |
| Support Level | $1.32 | $10.25 |
| Resistance Level | $1.62 | $15.11 |
| Average True Range (ATR) | 0.06 | 0.97 |
| MACD | -0.01 | 0.18 |
| Stochastic Oscillator | 47.83 | 51.18 |
Nano Dimension Ltd provides industrial manufacturing solutions for the design-to-manufacturing of electronics and mechanical parts. These solutions are based on a combination of hardware, software, and materials science technologies. The solutions include industrial machinery, such as those for additive manufacturing, surface-mount technology, and industrial inkjet printing, along with software for design, simulation, and manufacturing management, as well as materials or consumables that are used by the machinery. These solutions are used by industrial customers in aerospace & defense, automotive, electronics, medical, research, and academia, along with government organizations.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.